Geisinger Medical Laboratories Test Catalog
HU, YO, AND RI ANTIBODIES WITH REFLEX TO TITERS AND WESTERN BLOT |
||
ORDERING INFORMATION: |
Geisinger Epic Procedure Code: LAB1309 Geisinger Epic ID: 53161 | |
SPECIMEN COLLECTION |
||
Specimen type: |
Serum | |
Preferred collection container: |
||
Alternate Collection Container: |
6 mL red-top (plain, non-serum separator) tube
|
|
Specimen required: |
1.5 mL serum; minimum 0.6 mL. | |
Patient preparation: |
Overnight fasting preferred. | |
SPECIMEN PROCESSING |
||
Specimen processing instructions: |
Centrifuge and aliquot. | |
Transport temperature: |
Room temperature. | |
Specimen stability: |
Room temperature: 7 days. Refrigerated: 14 days. Frozen: 21 days. | |
TEST DETAILS |
||
Additional information: |
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. | |
CPT code(s): |
86255 x3 | |
Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
|
|
Methodology: |
Immunofluorescence Assay |
|
Synonyms: |
Quest test code 90138, Hu Yo Ri AB
|
|
Clinical significance: |
Hu anti-neuronal nuclear antibody (anti-Hu) is found in 5-10% of patients with small cell carcinoma of the lung. Purkinje cell (Yo) antibody is found in patients with paraneoplastic cerebellar degeneration and is associated with breast, ovarian, and other gynecologic cancers. Some patients with ovarian cancer have low titers of Yo antibodies in the absence of cerebellar degeneration. Anti-Hu antibodies are associated with paraneoplastic encephalomyelitis and sensory neuropathy. Anti-Ri antibody can be detected in patients with paraneoplastic opsoclonus/myoclonus syndrome. Neoplasms most often associated with anti-Ri include breast cancer, small cell lung cancer, and gynecological cancers. |